Image credits: © BIOTYPE GmbH
BIOTYPE presents a comprehensive upgrade of its MODAPLEX platform. The benchtop diagnostics platform for the fully integrated analysis of molecular biomarker signatures has been available since September. With MODAPLEX, professional laboratories in research and clinics can now carry out highly specialised molecular analyses quickly and easily in an automated manner. Thanks to the compact and powerful MODAPLEX technology, the most important biomarkers relevant to decision-making can be detected and analysed simultaneously and in a few simple steps. The Dresden-based molecular diagnostics company has been investing in the development, production and marketing of molecular test systems for the detection of disease-relevant genetic changes for over ten years. BIOTYPE is now launching the next generation of its hardware platform and simplifying the software for automated data analysis for the detection and quantification of cancer-relevant RNA and DNA biomarkers. The MODAPLEX platform is an open system solution. BIOTYPE enables third parties, e.g. manufacturers of molecular test systems or pharmaceutical companies, to develop and commercialise their own assays. This approach expands the market of available tests and increases the attractiveness of MODAPLEX for users who want to obtain their test kits from multiple sources.
BIOTYPE enters the systems business
„The further development of the MODAPLEX platform is also our entry into the international systems business for molecular diagnostics,
says Dr Norman Gerstner, Managing Director of BIOTYPE GmbH. „Last year, we repositioned the company in the rapidly developing market of precision medicine. In addition to molecular tests for the highly specialised diagnosis of complex diseases, our portfolio is now being expanded to include software and devices. „In addition, MODAPLEX is making an important contribution to meeting the growing demand for advanced technologies for multi-gene testing. MODAPLEX maximises the use of existing tissue samples and shortens critical turnaround times“, says Norman Gerstner. In less than four hours, the MODAPLEX platform's automated workflow delivers fast and accurate results for pathologists and clinicians. During this time, the decision-relevant RNA and DNA biomarkers are measured simultaneously from a sample. On this basis, the best possible therapy can be initiated. BIOTYPE thus also makes a significant contribution to reducing the burden on the healthcare system.
Molecular diagnostics for precision medicine is a rapidly growing market worldwide
Precision medicine, also known as personalised medicine, has experienced a strong upswing, especially in modern cancer medicine. Treatment is individually tailored to the unique characteristics of the patient, which enables more effective therapies with fewer side effects. The prerequisite for this is targeted, biomarker-based diagnostics that identify a patient's disease-relevant genetic and molecular factors. This enables more effective treatments with fewer side effects. Personalised medicine reduces the trial-and-error approach, saves time and minimises the burden on patients. This approach represents a breakthrough in healthcare and emphasises the importance of treating patients individually. „The global molecular diagnostics market generated revenues of almost EUR 17 billion in 2023, of which molecular precision diagnostics accounted for around one third. This market will grow at a double-digit percentage rate every year for the next five years and will make a significant contribution to the further development of medicine and the improvement of healthcare," says Dr Manja Böhme, Chief Commercial Officer at BIOTYPE.
BIOTYPE has more than 20 years of experience in the field of molecular diagnostics
The molecular diagnostics company BIOTYPE has been developing, producing and distributing test systems for molecular precision diagnostics for many years. These include test kits, software for automated data analysis and the MODAPLEX platform for the detection and quantification of RNA and DNA biomarkers. In Saxony, the company benefits from a unique Öcosystem of partners from industry, clinics and research. This competence network works together on new solutions for precision medicine. BIOTYPE has enjoyed a close partnership with the Carl Gustav Carus University Hospital in Dresden for many years. Professor Dr med. habil. Michael Albrecht, Medical Director of the Carl Gustav Carus University Hospital in Dresden, points out the increasing importance of the evidence-based interpretation of biomarkers in individualised and personalised medicine, which can be used to treat cancer in particular more successfully than before. „With its Cancer Research Centre, the Carl Gustav Carus University Hospital Dresden plays a leading role in the treatment of cancer in Germany. Together, we are working to help shape modern cancer medicine both nationally and internationally,
&about BIOTYPE
In 2019, BIOTYPE GmbH celebrated its 20th anniversary. Since the company was founded, the molecular diagnostics company from Dresden has gone through various stages. Back in the early 2000s, its forensic PCR kits played a decisive role in the establishment and expansion of the German DNA analysis database (DAD). Since then, the company has been involved in the development, production, validation and distribution of test systems for molecular genetic analysis (DNA and RNA tests) and in-vitro diagnostics (IVD). Today, BIOTYPE offers innovative molecular detection methods and diagnostics for precision medicine. The test systems support research, diagnostics and therapy in oncology, primarily for blood cancers and solid tumours.
BIOTYPE is currently evolving into a systems provider and entering the professional systems business. With its innovative MODAPLEX platform, BIOTYPE offers a benchtop device for the automated analysis of molecular biomarker signatures. The open platform approach enables scientists and other system users to develop their own assays for their own applications. MODAPLEX enables fast and cost-effective multi-gene analyses in precision oncology and infection diagnostics as well as in translational and clinical research. Based on this technology, new test procedures are currently being developed together with partners such as the Carl Gustav Carus University Hospital in Dresden in order to provide cancer patients with individualised diagnostics and thus better treatment decisions.
As a molecular genetic diagnostics company, BIOTYPE GmbH is part of the Molecular Diagnostics Group (MDG), which works together with the bioinformatics company, qualitype GmbH, and the radiopharmaceutical company, ROTOP Pharmaka GmbH, on holistic solutions for precision medicine.
More information: https://www.biotype.de
If you have any questions, please contact:
